Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 8/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658382 | 0.89 | PSMB5 (0.51) | PSMB5MMP1TP53RXFP1SMN1; SMN2 | |
| SCHEMBL15075897 | 0.88 | PSMB5 (0.48) | PSMB5MMP1TP53RXFP1SMN1; SMN2 | |
| SCHEMBL15075885 | 0.88 | PSMB5 (0.52) | PSMB5PSMB8 | |
| SCHEMBL15058629 | 0.88 | PSMB5 (0.52) | PSMB5PSMB8 | |
| SCHEMBL16280310 | 0.87 | PSMB5 (0.48) | PSMB5MMP1TP53RXFP1SMN1; SMN2 | |
| SCHEMBL15075926 | 0.87 | PSMB5 (0.48) | PSMB5MMP1TP53RXFP1SMN1; SMN2 | |
| SCHEMBL13061957 | 0.87 | PSMB5 (0.49) | PSMB5MMP1TP53RXFP1SMN1; SMN2 | |
| SCHEMBL15058611 | 0.86 | MME (0.49) | PSMB5SMN1; SMN2PSMB8 | |
| SCHEMBL15075957 | 0.86 | CAPN1 (0.58) | PSMB5NPC1RAB9APSMB8MEN1 | |
| SCHEMBL15075939 | 0.86 | CAPN1 (0.58) | PSMB5NPC1RAB9APSMB8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793900-B1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING SA (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | PSMB5 5/4885MMP1 2452/4885TP53 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.